Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab-Reference-Cited by-同舟云学术

Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab

Published:2016-02 Issue:1 Volume:38 Page:32-41
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Hock Barry D.,Stamp Lisa K.,Hayman Matthew W.,Keating Paula E.,Helms Esther T. J.,Barclay Murray L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Tailoring anti-TNF therapy in IBD: drug levels and disease activity.;Ben-Horin;Nat Rev Gastroenterol Hepatol,2014

2. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.;Bendtzen;Discov Med,2013

3. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.;Garces;Ann Rheum Dis,2013

4. . Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.;Paul;Inflamm Bowel Dis,2014

5. . Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.;Bartelds;JAMA,2011

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers;Current Rheumatology Reviews;2024-09

2. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory;Therapeutic Drug Monitoring;2024-04-09

3. Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study;The Journal of Rheumatology;2024-01-15

4. Four‐year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing;Internal Medicine Journal;2023-11

5. Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels;Heliyon;2023-11